MassDevice.com +5 | The top 5 medtech stories for May 18, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters. 5. Medtronic owes spine doc inventor $24m for patent infringement Medtronic must fork over nearly $24 million to the physician inventor behind a group of patents covering a technique for treating spine defects. Dr. Mark Barry sued Medtronic in February 2014 in the U.S. District Court for Eastern Texas, alleging infringement for 3 patents covering a “system and method for aligning vertebrae in the amelioration of aberrant spinal column deviation conditions.” Read more 4. FDA panel recommends approval TransMedics lung transplant device An FDA advisory panel yesterday recommended that the federal safety watchdog approve a device made by TransMedics to keep donated lungs perfused during transport to transplantation procedures. The FDA’s Gastroenterology &Urology Devices panel voted 11-2 that the OCS Lung system is safe; 8-5 that it’s effective; and 9-4 that its benefits outweigh the risks, an FDA spokeswoman told MassDevice.com via email. Read more 3. EuroPCR Roundup: Medtronic’s Resolute Onyx meets primary endpoint in small-vessel trial ...
(MedPage Today) -- This week's topics include the emotional consequences of gun violence, a single test to diagnose diabetes, use of medicines to help addiction after opioid overdose, and screening for abdominal aortic aneurysm
Conclusions Percutaneous transabdominal embolization is a safe and efficacious treatment for type II endoleak, with a short procedure time.
Retrospective analysis of a single-center experience.
Longitudinal study of patients entered at baseline between 1987 and 1989 in the Atherosclerosis Risk in Communities (ARIC) study from four U.S. communities in Mississippi, Maryland, Minnesota, and North Carolina.
Whereas the early mortality benefit of endovascular aneurysm repair (EVAR) over open repair for intact abdominal aortic aneurysms (AAAs) has been confirmed in numerous randomized trials and observational studies, the data regarding outcomes after repair of ruptured AAAs (rAAAs) are conflicting. As summarized in a recent Cochrane review, four randomized controlled trials failed to demonstrate improved short-term mortality after EVAR for rAAA.1 However, these trials were limited by small sample size, inclusion criteria leading to the exclusion of many patients, and frequent treatment variation from randomization.
This study's objective was to evaluate coding accuracy and its effect on hospital cost for patients undergoing EVAR.
The objective of this study was to assess outcomes of a hybrid technique for treatment of abdominal aortic aneurysm (AAA) associated with iliac aneurysm without distal neck by combining an AAA endovascular repair approach with open surgery for preservation of the internal iliac artery (IIA).
Strijbos et al. found that some 75% of patients with peripheral arterial disease (PAD) or an abdominal aortic aneurysm (AAA) have inadequate health literacy (HL), meaning that they are not able to obtain, process, or understand medical information adequately.1 This is a very important finding for all professi onals who treat patients with arterial disease. One might of course question the validity of the Newest Vital Sign (NVS) Dutch version and wonder how one can accurately measure HL using the nutritional information on an ice cream wrapping.
Abdominal aortic aneurysm (AAA) is three to five times more common among men compared with women, yet up to 38% of all aneurysm related deaths affect women. The aim of this study was to estimate the prevalence of synchronous or metachronous aneurysms among women with AAA, as diagnosis and treatment could improve survival.
Regulators say the company's AFX endovascular graft system with Strata material -- used for abdominal aortic aneurysm repair -- is at greater risk for type III endoleaks compared with other devices for the same indication.News Alerts